Building off the groundbreaking findings in Phase I, this is the first study to show a broad array of regenerative improvements, and have very exciting implications for patients moving forward. While further study of these results is needed, notable findings include:
Significant improvement in walking speeds among patients who require walking assistance
Improved bladder function, with 69% of patients showing improved post-void residual volume
A positive increase in gray matter volume for patients with less advanced disease progression, indicating the treatments could potentially restore neuronal cells and reverse cognitive decline in these patients
Notable biomarker changes, including a decrease in the protein CCL2 (which is associated with inflammatory diseases like MS) and an increase in the protein MMP9 (which indicates an increase in microglial cells that repair the progression of MS)
Dr. Sadiq shared these results at the American Academy of Neurology annual meeting in Boston in April, and we’ll be sure to share further updates as we prepare the paper manuscript for publication.
Find our press release below.
FDA-Approved Phase II Stem Cell Treatment Trial Shows Significant and Diverse Improvements for Multiple Sclerosis (MS) Patients
The study, from the Tisch MS Research Center of New York, is the first to link stem cells with a broad array of improvements in multiple areas
Progressive MS patients demonstrated better outcomes in walking speeds, gray matter volume, bladder function, and biomarker indicators
The Tisch MS Research Center of New York, the world’s largest independent research center focused on MS, today announced the Phase II results of its FDA-approved stem cell treatment study. The research is a continuation of a Phase I trial, which was the first ever in the U.S. to receive FDA approval to investigate the injection of stem cells into the cerebrospinal fluid of MS patients. The Phase II trial showed improvements across multiple areas in progressive MS patients with significant disability.
“The findings of this study suggest that stem cells could have major implications for treating MS and reversing patient disability even after significant progression”
Among patients who require walking assistance, those who received stem cell treatments saw a significantly higher percentage of improvement in both a timed 25-foot walk test and a 6-minute walking test than those in the control group. These results suggest that stem cell treatments could be correlated with walking improvement, a finding that could have major implications for quality of life for progressive MS patients struggling with motor function.
The study also found a positive increase in gray matter volume among patients who began the trial with normalized gray matter above the 50th percentile. This indicates that stem cells could restore neuronal cells and potentially reverse cognitive decline in patients with less advanced disease progression. Additionally, patients who received the stem cell treatments showed improved bladder function, with 69% of patients showing improved post-void residual volume.
The stem cell treatments also resulted in notable biomarker changes in patients’ cerebrospinal fluid. Those who received the stem cell treatments showed decreased levels of the protein CCL2 (which is associated with inflammatory diseases like MS), as well as an increase in the protein MMP9 (a potential indicator of an increase in reparative microglial cells) compared to the control group. As a result, these biomarkers may provide a valuable mechanism to measure treatment response in future studies.
“These findings are unprecedented in the realm of researching stem cells as a treatment pathway for progressive MS patients. They represent the first time we have seen a regenerative treatment improve patient outcomes in multiple areas, providing strong evidence of the potential efficacy of stem cells in patients with significant and varying disabilities,” said Saud A. Sadiq, Director and Chief Research Scientist of the Tisch Center. “We are particularly encouraged by the improvements in walking speed among patients who require assistance, which suggests that stem cells can make a potentially life-altering difference for these patients. Furthermore, the biomarker changes observed in the study show biochemical evidence of the reparative nature of stem cell treatments and can provide a valuable metric for us to further study their impact.”
In 2014, the Phase I results of the Tisch Center’s stem cell treatment study were the first ever to show reversal of established disability in MS from stem cells. A follow-up study of those patients from Phase 1 showed that a subset of the patients sustained clinical improvement and that there were no long-term side effects for any of the participants.
The Phase II trial began in 2018 and was a randomized, double-blind, placebo-controlled clinical study with 54 patients. The study had a compassionate cross-over design, in which patients who received the stem cell treatment in the first year received the placebo in the second year (and vice versa). Patients received six injections (of either autologous MSC-NPs or saline injections) every two months.
As a next step, the Center is exploring an investigation of the effects of increasing the stem cell dosage that patients receive.
“The findings of this study suggest that stem cells could have major implications for treating MS and reversing patient disability even after significant progression,” added Dr. Violaine Harris, a principal investigator at the Tisch Center and lead author of the study. “We look forward to building on these findings in future research and potentially studying the effects of increasing the dosage of stem cells administered to patients.”